LZLemeng Zhang

Lemeng Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lemeng Zhang has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Tianli Cheng

    Thoracic Medicine Department 1, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan Province 410013, PR China

    9 shared publications
  • Zhou Jiang

    Thoracic Medicine Department 1, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan Province 410013, PR China

    8 shared publications
  • Hua Yang

    Thoracic Medicine Department 1, Hunan Cancer Hospital, Changsha, Hunan Province, People's Republic of China

    7 shared publications
  • Changqie Pan

    Thoracic Medicine Department 1, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan Province 410013, PR China

    6 shared publications
  • Yongzhong Luo

    Thoracic Medicine Department 1, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan Province 410013, PR China

    6 shared publications
  • Yongzhong Luo

    Thoracic Medicine Department, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Tongzipo Rd 283#, Yuelu District, Changsha 410013, China

    6 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    Optical probes for bioimaging of tumor-infiltrating immune cells and their applications in cancer immunotherapy

    by Xinglong Chen, Cong Hu, Heejeong Kim, Lemeng Zhang, Zhipengjun Zhang, Hongwen Liu, Juyoung Yoon

    Optical probes and their applications in biomedicine.


  • Synergistic effects of neutrophil extracellular traps and NF-κB on promoting tumor progression and immune evasion in lung adenocarcinoma

    by Yuning Li, Houwu Gong, Xinglong Chen, Jialin Su, Yifan Yang, Yongzhong Luo, Tianli Cheng, Changqie Pan, Haitao Li, Zhou Jiang, et al.


  • Open Access

    Case Report: A case of first-line treatment for rare ROS1 fusion mutation lung adenocarcinoma with entrectinib

    by Yifan Yang, Qing Yi, Wei Yang, Yongzhong Luo, Lemeng Zhang

    The incidence of the ROS1 fusion mutation (ROS proto-oncogene 1) in non-small cell lung cancer (NSCLC) is approximately 1-2%. At least 55 partner genes have been identified that can fuse with ROS1.Herein, we report a case of a lung adenocarcinoma patient harboring a rare ROS1 fusion mutation with brain metastasis, who achieved good control of both lung and intracranial lesions after treatment with Entrectinib. A 68-year-old female patient with no smoking history presented with a cough and headache. She was diagnosed with advanced lung adenocarcinoma, stage T1cN3M1c IVb, which included multiple brain metastases. An IGR (downstream MAN1A1) ROS1:exon34 fusion was detected at a mutant allele frequency (MAF) of 12.73%, accompanied by two TP53 mutations c.1024C>T (p.R342*) and c.686_687del (p.C229Yfs*10). The resultant fusion protein preserves the whole TRKA kinase domain of ROS1, and therefore may constitutively activate ROS1.Therefore, RNA-seq was conducted to further confirm the expression of IGR-ROS1 fusion at mRNA level. A CD74:exon6 ~ ROS1: exon 35 fusion was identified, which could mediate the full kinase function. A biopsy of the right supraclavicular lymph node confirmed the diagnosis of lung adenocarcinoma. She was diagnosed with advanced lung adenocarcinoma, stage T1cN3M1c IVb, which included multiple brain metastases. The patient began treatment with entrectinib (600 mg, once daily) as a first-line therapy. At the time of diagnosis, the patient reported headaches and experienced sleep disturbances. Subsequently, the patient underwent whole-brain radiotherapy. Significant improvements were noted in her headache and insomnia symptoms. After one month, the longest diameter of the left upper lung nodule decreased from 19 mm to 12 mm, and there was a notable reduction in the right hilar and mediastinal lymph nodes. Additionally, the patient’s intracranial metastatic lesion reduced in size from 19 mm to 8 mm, leading to an improvement in her headache symptoms. It is worth further exploring whether patients carrying IGR fusions can receive targeted therapy.

  • Open Access

    Enhancing clinical precision in lung cancer tissue biopsy through elevated response-threshold of an endoplasmic reticulum-targeted fluorogenic probe

    by Zhiyang Yuwen, Xinglong Chen, Kexin Chen, Tenglong Zou, Guojiang Mao, Hongwen Liu, Lemeng Zhang


  • Top Cited Papers
    Open Access

    Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis

    by Jialin Su, Yuning Li, Shuhua Tan, Tianli Cheng, Yongzhong Luo, Lemeng Zhang

    This study aimed to systematically investigate the value of the pre-treatment neutrophil-to-lymphocyte ratio (NLR) in prognosticating the outcome of patients with advanced cancer receiving immunotherapy. We searched Embase, PubMed, Web of Science, and Cochrane Library to identify studies about cancer patients with immunotherapy until November 29, 2024. Retrospective or prospective cohort studies with pretreatment NLR data were included. The odds ratio (OR) and 95% confidence interval (CI) were calculated to evaluate the predictive value of NLR in prognosis and immunotherapy efficacy. The random effect model was applied for meta-analysis and the risk of bias was assessed by Egger test and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method. A total of 129 articles involving 18780 cases were finally selected. Most cases were advanced cancers with the median follow-up period ranged 2–48.6 months. The high pretreatment NLR level was associated with the significantly reduced OS (HR (95%CI) = 2.26 (2.03, 2.53)), PFS (HR (95% CI) = 1.83 (1.69, 1.98)), ORR (OR (95%CI) = 0.53 (0.46, 0.61)) and DCR (OR (95% CI) = 0.36 (0.29, 0.43)) in patients with advanced cancer receiving immunotherapy. The quality of evidence was low, attributed to the serious risk of bias and incon¬sistency. An elevated NLR before immunotherapy was significantly associated with poor clinical outcomes in patients with advanced cancer.


  • Open Access

    Progression in Near-Infrared Fluorescence Imaging Technology for Lung Cancer Management

    by Xinglong Chen, Yuning Li, Jialin Su, Lemeng Zhang, Hongwen Liu

    Lung cancer is a major threat to human health and a leading cause of death. Accurate localization of tumors in vivo is crucial for subsequent treatment. In recent years, fluorescent imaging technology has become a focal point in tumor diagnosis and treatment due to its high sensitivity, strong selectivity, non-invasiveness, and multifunctionality. Molecular probes-based fluorescent imaging not only enables real-time in vivo imaging through fluorescence signals but also integrates therapeutic functions, drug screening, and efficacy monitoring to facilitate comprehensive diagnosis and treatment. Among them, near-infrared (NIR) fluorescence imaging is particularly prominent due to its improved in vivo imaging effect. This trend toward multifunctionality is a significant aspect of the future advancement of fluorescent imaging technology. In the past years, great progress has been made in the field of NIR fluorescence imaging for lung cancer management, as well as the emergence of new problems and challenges. This paper generally summarizes the application of NIR fluorescence imaging technology in these areas in the past five years, including the design, detection principles, and clinical applications, with the aim of advancing more efficient NIR fluorescence imaging technologies to enhance the accuracy of tumor diagnosis and treatment.


  • Open Access

    Machine learning based on metabolomics unveils neutrophil extracellular trap-related metabolic signatures in non-small cell lung cancer patients undergoing chemoimmunotherapy

    by Yu-Ning Li, Jia-Lin Su, Shu-Hua Tan, Xing-Long Chen, Tian-Li Cheng, Zhou Jiang, Yong-Zhong Luo, Le-Meng Zhang

    BACKGROUND Non-small cell lung cancer (NSCLC) is the primary form of lung cancer, and the combination of chemotherapy with immunotherapy offers promising treatment options for patients suffering from this disease. However, the emergence of drug resistance significantly limits the effectiveness of these therapeutic strategies. Consequently, it is imperative to devise methods for accurately detecting and evaluating the efficacy of these treatments. AIM To identify the metabolic signatures associated with neutrophil extracellular traps (NETs) and chemoimmunotherapy efficacy in NSCLC patients. METHODS In total, 159 NSCLC patients undergoing first-line chemoimmunotherapy were enrolled. We first investigated the characteristics influencing clinical efficacy. Circulating levels of NETs and cytokines were measured by commercial kits. Liquid chromatography tandem mass spectrometry quantified plasma metabolites, and differential metabolites were identified. Least absolute shrinkage and selection operator, support vector machine-recursive feature elimination, and random forest algorithms were employed. By using plasma metabolic profiles and machine learning algorithms, predictive metabolic signatures were established. RESULTS First, the levels of circulating interleukin-8, neutrophil-to-lymphocyte ratio, and NETs were closely related to poor efficacy of first-line chemoimmunotherapy. Patients were classed into a low NET group or a high NET group. A total of 54 differential plasma metabolites were identified. These metabolites were primarily involved in arachidonic acid and purine metabolism. Three key metabolites were identified as crucial variables, including 8,9-epoxyeicosatrienoic acid, L-malate, and bis(monoacylglycerol)phosphate (18:1/16:0). Using metabolomic sequencing data and machine learning methods, key metabolic signatures were screened to predict NET level as well as chemoimmunotherapy efficacy. CONCLUSION The identified metabolic signatures may effectively distinguish NET levels and predict clinical benefit from chemoimmunotherapy in NSCLC patients.


  • Open Access

    Clinical significance and biological function of interferon regulatory factor 1 in non-small cell lung cancer

    by Jialin Su, Shuhua Tan, Yuning Li, Xinglong Chen, Jiasi Liu, Yongzhong Luo, Changqie Pan, Lemeng Zhang

    The clinical application and biological function of interferon regulatory factor 1 (IRF1) in non-small cell lung cancer (NSCLC) patients undergoing chemoimmunotherapy remain elusive. The aim of this study was to investigate the predictive and prognostic significance of IRF1 in NSCLC patients. We employed the cBioPortal database to predict frequency changes in IRF1 and explore its target genes. Bioinformatic methods were utilized to analyze the relationship between IRF1 and immune regulatory factors. Retrospective analysis of clinical samples was conducted to assess the predictive and prognostic value of IRF1 in chemoimmunotherapy. Additionally, A549 cells with varying IRF1 expression levels were constructed to investigate its effects on NSCLC cells, while animal experiments were performed to study the role of IRF1 in vivo. Our findings revealed that the primary mutation of IRF1 is deep deletion and it exhibits a close association with immune regulatory factors. KRAS and TP53 are among the target genes of IRF1, with interferon and IL-2 being the predominantly affected pathways. Clinically, IRF1 levels significantly correlate with the efficacy of chemoimmunotherapy. Patients with high IRF1 levels exhibited a median progression-free survival (mPFS) of 9.5 months, whereas those with low IRF1 levels had a shorter mPFS of 5.8 months. IRF1 levels positively correlate with PD-L1 distribution and circulating IL-2 levels. IL-2 enhances the biological function of IRF1 and recapitulates its role in vivo in the knockdown group. Therefore, IRF1 may possess predictive and prognostic value for chemoimmunotherapy in NSCLC patients through the regulation of the IL-2 inflammatory pathway.


  • Open Access

    Research progress on novel antibody drug conjugates in cancer therapy.

    by Yuning Li, Jialin Su, Shuhua Tan, Yongzhong Luo, Lemeng Zhang

    Traditional antibody drug conjugates (ADC) combine monoclonal antibodies with cytotoxic drugs to accurately strike cancer cells, but there are still many shortcomings in stability, targeting, efficacy, and safety. Novel ADC, such as bi-specific, site-specific, dual-payload, and pro-drug type ADC, can be optimized by simultaneously binding 2 different antigens or epitopes, selecting more stable linkers, coupling with specific amino acid sites of antibodies, carrying different drug payloads, and adopting prodrug strategies, while retaining the characteristics of traditional ADC. Significantly improving the stability, targeting, efficacy and safety of drugs can better meet the needs of clinical treatment. Novel ADC will play a more important role in cancer treatment in the future. Discussing the progress of novel ADC in cancer treatment and analyzing their advantages and challenges can provide theoretical support for the development of anti-cancer strategies and provide directions for drug research and development.


  • Open Access

    The Evaluation of Prognostic Value and Immune Characteristics of Ferroptosis-Related Genes in Lung Squamous Cell Carcinoma

    by Jialin Su, Shuhua Tan, Houwu Gong, Yongzhong Luo, Tianli Cheng, Hua Yang, Xiaoping Wen, Zhou Jiang, Yuning Li, Lemeng Zhang

    Background The purpose of our study was to construct a prognostic model based on ferroptosis-related gene signature to improve the prognosis prediction of lung squamous carcinoma (LUSC). Methods The mRNA expression profiles and clinical data of LUSC patients were downloaded. LUSC-related essential differentially expressed genes were integrated for further analysis. Prognostic gene signatures were identified through random forest regression and univariate Cox regression analyses for constructing a prognostic model. Finally, in a preliminary experiment, we used the reverse transcription-quantitative polymerase chain reaction assay to verify the relationship between the expression of three prognostic gene features and ferroptosis. Results Fifty-six ferroptosis-related essential genes were identified by using integrated analysis. Among these, three prognostic gene signatures (HELLS, POLR2H, and POLE2) were identified, which were positively affected by LUSC prognosis but negatively affected by immune cell infiltration. Significant overexpression of immune checkpoint genes occurred in the high-risk group. In preliminary experiments, we confirmed that the occurrence of ferroptosis can reduce three prognostic gene signature expression. Conclusions The three ferroptosis-related genes could predict the LUSC prognostic risk of antitumor immunity. L.M. and Y.L. contributed to manuscript preparation. L.Z. and S.T. contributed to the study design, manuscript writing, and data analysis. H.G. and J.S. contributed to clinical data collection. J.S., S.T., H.Y., X.W., and Z.J. contributed to molecular experiments and data statistics analysis. All authors read and approved the final manuscript. Not applicable. Not applicable. The raw data, supporting the conclusions of this manuscript, will be made available by contacting the corresponding author. This article does not contain any studies with human participants performed by any of the authors. The data from TCGA are publicly available. Thus, the present study was exempted from the approval of local ethics committees. The current research follows the TCGA data access policies and publication guidelines. All data submitted to the TCGA database have been ethically approved. The TCGA data citation guidelines and licenses have been followed. * The authors contribute to the manuscript equally. Article published online: 30 October 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany